Abell Foundation
http://www.abell.org
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Abell Foundation
Venture Funding Deals, April 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced February through March 2015.
BioMarker Strategies LLC
Targeted cancer drugs are all the rage--and with good reason--but it remains challenging to accurately predict which patients will respond to them. BioMarker Strategies LLC has developed SnapPath, an ex vivo biomarker system that disperses solid tumor tissue in media. It then exposes live cells to growth factors and other stimuli to induce them to produce phosphoproteins and other ex vivo biomarkers to reveal the functional circuitry of the patient's tumor cells.
Company Information
- Industry
- Academic and Research Institutions
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice